P
Paul J.W.H. Kappelle
Researcher at University Medical Center Groningen
Publications - 21
Citations - 577
Paul J.W.H. Kappelle is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Cholesterol & Apolipoprotein B. The author has an hindex of 14, co-authored 21 publications receiving 538 citations. Previous affiliations of Paul J.W.H. Kappelle include University of Groningen.
Papers
More filters
Journal ArticleDOI
Apolipoprotein B/A‐I and total cholesterol/high‐density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C‐reactive protein
Paul J.W.H. Kappelle,Ron T. Gansevoort,J. L. Hillege,Bruce H. R. Wolffenbuttel,Robin P. F. Dullaart +4 more
TL;DR: Apolipoprotein B/A‐I and total cholesterol/high‐density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C‐reactive protein.
Journal ArticleDOI
Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.
Paul J.W.H. Kappelle,Jan Freark de Boer,Frank G. Perton,Wijtske Annema,Rindert de Vries,Robin P. F. Dullaart,Uwe J. F. Tietge +6 more
TL;DR: In this paper, the authors investigated whether the antioxidative functionality of HDL is altered in type 2 diabetes mellitus and aimed to identify potential determinants of this parameter, including hyperglycaemia, increased LCAT activity and lower PON-1 activity.
Journal ArticleDOI
The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: A prospective nested case-control study
Paul J.W.H. Kappelle,Robin P. F. Dullaart,André P van Beek,Hans L. Hillege,Bruce H. R. Wolffenbuttel +4 more
TL;DR: This study suggests that the L/A ratio may be a preferential marker of a first cardiovascular event in men compared to plasma leptin and adiponectin levels alone.
Journal ArticleDOI
Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome.
TL;DR: It is suggested that higher SAA levels contribute to impaired HDL anti-oxidative function in MetS via an effect on PON-1 regulation.
Journal ArticleDOI
Cholesteryl Ester Transfer Protein Inhibition in Cardiovascular Risk Management: Ongoing Trials will End the Confusion
TL;DR: Serious concerns remain about the validity of the concept that HDL cholesterol raising by means of CETP inhibition is a viable strategy, and results of ongoing clinical trials with these drugs will have to be awaited before making up the balance between possible benefits and harms related to pharmacological CETP inhibitor.